Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03828474 · ClinicalTrials.gov registry record · Phase 1
Sickness Evaluation at Altitude With Acetazolamide at Relative Doses
A Phase 1 study, sponsored by Stanford University.
- Completed
- Registry status
- Phase 1
- Development phase
- 108
- Enrollment target
NCT03828474: Completed Phase 1 study, sponsored by Stanford University.
NCT03828474 is a Phase 1 study that has completed, run by Stanford University. The registered enrollment target is 108 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03828474, a Phase 1 study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 108 participants
- Enrollment target
Study Summary
The specific aim of this study is to evaluate whether acetazolamide 125mg daily is no worse than acetazolamide 250mg daily in decreasing the incidence of acute mountain sickness (AMS) in travelers to high altitude. The study population is hikers who are ascending at their own rate under their own power in a true hiking environment at the White Mountain Research Station, Owen Valley Lab (OVL) and Bancroft Station (BAR), Bancroft Peak, White Mountain, California
Interventions
- DRUG Acetazolamide Pill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 108 participants |
| Start Date | 2019-08-09 |
| Est. Completion | 2019-09-29 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03828474
The ClinicalTrials.gov registry entry for NCT03828474 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 108 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Acetazolamide Pill is the first listed.
NCT03828474 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03828474 about?
NCT03828474 is a clinical study titled "Sickness Evaluation at Altitude With Acetazolamide at Relative Doses". The specific aim of this study is to evaluate whether acetazolamide 125mg daily is no worse than acetazolamide 250mg daily in decreasing the incidence of acute mountain sickness (AMS) in travelers to high altitude. The study population is hikers who are ascending at their own rate under their own po...
What is the current status of trial NCT03828474?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 108 participants. The study started on 2019-08-09. Estimated completion is 2019-09-29.
What interventions are being tested in trial NCT03828474?
The interventions under investigation include: Acetazolamide Pill (DRUG).
Who is sponsoring clinical trial NCT03828474?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.